Not known Factual Statements About sodium pentobarbital
Not known Factual Statements About sodium pentobarbital
Blog Article
pentobarbital will lower the extent or effect of phenytoin by influencing hepatic enzyme CYP2C9/10 metabolism. Use Caution/Watch.
pentobarbital will minimize the level or effect of atogepant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Advised atogepant dosage with concomitant usage of powerful or moderate CYP3A4 inducers is thirty mg or sixty mg qDay.
pentobarbital will reduce the extent or effect of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
Administer barbiturates with caution in sufferers with hepatic harm and at lessened doses originally; barbiturates really should not be administered to people displaying the premonitory signs of hepatic coma
Phenytoin, sodium valproate, valproic acid: The effect of barbiturates around the metabolism of phenytoin seems to be variable. Some investigators report an accelerating effect, whilst others report no effect. Because the effect of barbiturates around the metabolism of phenytoin isn't predictable, phenytoin and barbiturate blood amounts must be monitored far more usually if these drugs are provided concurrently.
Exercise warning when administered to people with acute or chronic pain; could bring about paradoxical exhilaration or vital symptoms could be masked
pentobarbital will minimize the extent or effect of abiraterone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lessen the level or effect of suvorexant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Robust CYP3A4 inducers could minimize suvorexant efficacy; if greater suvorexant dose necessary, will not exceed website twenty mg/working day
pentobarbital will decrease the level or effect of itraconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
fentanyl intranasal and pentobarbital both enhance sedation. Stay clear of or Use Alternate Drug. Limit use to patients for whom alternative procedure choices are inadequate
pentobarbital will lessen the level or effect of irinotecan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the extent or effect of zonisamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.
pentobarbital will reduce the extent or effect of acalabrutinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will reduce the extent or effect of cannabidiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Consider an increase in cannabidiol dosage (based on medical reaction and tolerability) when coadministered with a powerful CYP3A4 inducer.